Literature DB >> 15801547

Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica.

L Mottier1, G Virkel, H Solana, L Alvarez, J Salles, C Lanusse.   

Abstract

Triclabendazole (TCBZ) is an halogenated trematodicidal benzimidazole compound extensively used in veterinary medicine. It is active against immature and adult stages of the liver fluke Fasciola hepatica. Free and conjugated TCBZ metabolites have been identified in the bile of treated sheep. The experimental aims were to characterize the in vitro patterns of TCBZ biotransformation both in the animal host (sheep liver microsomes) and target parasite (F. hepatica microsomal preparation); and to compare the ex vivo diffusion of TCBZ parent drug and its oxidized metabolites (TCBZ sulphoxide [TCBZSO], TCBZ sulphone [TCBZSO2], and TCBZ-hydroxy derivatives) into F. hepatica. Additionally, the octanol-water partition coefficients for TCBZ and all its metabolites were estimated as an indicator of the relationship between drug lipophilicity and diffusion into the target parasite. Drug/metabolites concentrations were quantified by HPLC after sample clean up and a solvent-mediated chemical extraction. Sheep liver microsomes metabolized TCBZ into its sulphoxide and sulphone metabolites after 30 min of incubation. The rate of TCBZ sulphoxidation in the liver was significantly greater (p < 0.01) than that observed for the sulphonation of TCBZSO. The trematode parasite oxidized TCBZ into its sulphoxide metabolite after 60 min of incubation at a metabolic rate of 0.09 nmol min(-1) mg protein(-1). TCBZ and all its oxidized metabolic products were recovered from F. hepatica as early as 15 min after their ex vivo incubation in a Kreb's Ringer Tris buffer. However, the diffusion of the hydroxy-derivatives into the fluke was lower than that observed for TCBZ, TCBZSO and TCBZSO2. There was a high correlation (r=0.82) between drug lipophilicity (expressed as octanol-water partition coefficients) and drug availability measured within the parasite. Unlike the uptake pattern previously observed for albendazole, the parent TCBZ and its sulphoxide and sulphone metabolites showed a similar ability to penetrate into the trematode parasite. Understanding the relationship between TCBZ metabolism, the relative pharmacological potency of its metabolic products and their ability to reach the target parasite may be critical to optimize its flukicidal activity, particularly when TCBZ resistant flukes have been already isolated in the field.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15801547     DOI: 10.1080/00498250400015285

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-03-25       Impact factor: 2.289

2.  Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-03-26       Impact factor: 2.289

3.  Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-08-14       Impact factor: 2.289

4.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

5.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.

Authors:  David Richter; Joachim Richter; Beate Grüner; Kathrin Kranz; Juliane Franz; Peter Kern
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

6.  Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica.

Authors:  H Solana; S Scarcella; G Virkel; C Ceriani; J Rodríguez; C Lanusse
Journal:  Vet Res Commun       Date:  2008-08-26       Impact factor: 2.459

7.  Spatial visualization of drug uptake and distribution in Fasciola hepatica using high-resolution AP-SMALDI mass spectrometry imaging.

Authors:  Carolin M Morawietz; Alejandra M Peter Ventura; Christoph G Grevelding; Simone Haeberlein; Bernhard Spengler
Journal:  Parasitol Res       Date:  2022-01-24       Impact factor: 2.289

8.  Similarities and differences in the biotransformation and transcriptomic responses of Caenorhabditis elegans and Haemonchus contortus to five different benzimidazole drugs.

Authors:  S J Stasiuk; G MacNevin; M L Workentine; D Gray; E Redman; D Bartley; A Morrison; N Sharma; D Colwell; D K Ro; J S Gilleard
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-09-09       Impact factor: 4.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.